What topics does this cannabis study cover?

This study covers research on: CBD, Cancer, Inflammation.

Where was this research published?

Published in Neoplasma on August 4, 2026.

A neuroimmune cancer regimen is linked to longer survival

Neuroimmune treatment of advanced solid tumors: 3-year survival after angiotensin 1-7, pineal indoles, and cannabinoids.

Neoplasma • August 4, 2026 • Highly Relevant

🤖

AI Summary

This single-arm interventional study examined a neuroimmune treatment regimen for patients with advanced solid tumors that had stopped responding to standard treatments and had an estimated life expectancy of less than six months. The full regimen combined angiotensin 1–7, pineal compounds (melatonin and 5-methoxytryptamine), and cannabinoids—cannabidiol or cannabigerol for glioblastoma. It was compared with earlier patients who received the pineal compounds and cannabinoids without angiotensin 1–7.

Disease control was reported in 67 of 100 patients receiving the full regimen, with objective tumor regression in 23%. In the historical comparison group, disease control occurred in 111 of 212 patients and tumor regression in 8%. Three-year overall survival was 37% with the full regimen versus 19% with the earlier regimen. Both groups also showed increases in the lymphocyte-to-monocyte ratio, which the authors interpreted as suggesting improved systemic immune status. Because the comparison group was historical and the study was not randomized, these findings show an association rather than proving that adding angiotensin 1–7 or cannabinoids caused the improved outcomes; they should not be taken as evidence that this regimen is an established cancer treatment.

💡 Key Findings

The full neuroimmune regimen was associated with disease control in 67 of 100 patients, while objective tumor regression occurred in 23%.

Moderate

55%

Three-year overall survival was 37% with angiotensin 1–7 added to pineal indoles and cannabinoids, compared with 19% in the historical comparator cohort.

Moderate

55%

The authors report that adding angiotensin 1–7 was associated with improved disease control and long-term survival, but the nonrandomized historical comparison cannot establish causation.

Good

65%

Both treatment groups showed a significant increase in the lymphocyte-to-monocyte ratio, interpreted by the authors as suggesting improved systemic immune status.

Moderate

50%

📄 Original Abstract

In a recent study, the exogenous administration of angiotensin 1-7 (Ang 1,7) together with melatonin, 5-methoxytryptamine, and cannabidiol increased 1-year survival in advanced cancer patients, underlining the utility of neuromodulation in oncology. We now report a single-arm interventional study to evaluate the effectiveness of introducing Ang 1-7 in the neuroimmune regime, including pineal indoles and cannabinoids. Two cohorts of patients with advanced solid tumors refractory to standard oncologic treatments and with an estimated life expectancy of less than six months were studied. The full neuroimmune regimen cohort consisted of 100 consecutive patients treated over the last three years with Ang 1-7, pineal indoles, and cannabinoids, while the comparator cohort included 212 consecutive patients treated between 2015 and 2019 with pineal indoles and cannabinoids alone. Gastroprotected capsules of Ang 1-7 coupled with cyclodextrin were administered at 0.5 mg p.o. twice/day. Melatonin (100 mg) and 5-methoxytryptamine (20 mg) were given p.o. at bedtime and in the early afternoon, respectively. Cannabidiol or cannabigerol (in the case of glioblastoma) was given at 20 mg p.o. twice/day. Clinical response, disease control, and overall survival, along with the lymphocyte-to-monocyte ratio, were evaluated. In the full regimen cohort, disease control was achieved in 67 of 100 patients, with objective tumor regression observed in 23%. In the comparator cohort, disease control was obtained in 111 of 212 patients, with objective regression in 8%. Three-year overall survival was significantly higher in the full regimen cohort (37%) compared with the comparator cohort (19%). Both treatments were associated with a significant increase in the lymphocyte-to-monocyte ratio, suggesting an improvement in systemic immune status. The addition of Ang 1-7 to a neuroimmune regimen combining pineal indoles and cannabinoids was associated with improved disease control and long-term survival in patients with end-stage solid tumors lacking effective therapeutic options.